Zacks Investment Research upgraded shares of Auris Medical Holding AG (NASDAQ:EARS) from a hold rating to a buy rating in a research note published on Wednesday morning. The firm currently has $0.75 target price on the biotechnology company’s stock.

According to Zacks, “Auris Medical Holding AG is a biopharmaceutical company. It focuses on developing therapies for the treatment of hearing loss and tinnitus. The Company has two projects in advanced clinical development: AM-101 for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. Auris Medical Holding AG is headquartered in Zug, Switzerland. “

Several other brokerages have also commented on EARS. ValuEngine lowered Auris Medical Holding AG from a sell rating to a strong sell rating in a research report on Friday, June 2nd. Roth Capital reissued a buy rating and set a $5.00 price objective on shares of Auris Medical Holding AG in a research report on Saturday, July 1st. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus price target of $3.25.

Auris Medical Holding AG (EARS) traded up 14.1417% on Wednesday, reaching $0.7248. 1,546,487 shares of the company’s stock traded hands. The firm’s 50 day moving average price is $0.77 and its 200 day moving average price is $0.76. Auris Medical Holding AG has a 12 month low of $0.60 and a 12 month high of $2.09. The company’s market cap is $32.13 million.

Auris Medical Holding AG (NASDAQ:EARS) last released its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.09. On average, equities analysts expect that Auris Medical Holding AG will post ($0.63) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This report was originally published by Watch List News and is the property of of Watch List News. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://www.watchlistnews.com/auris-medical-holding-ag-ears-upgraded-at-zacks-investment-research/1538209.html.

A number of institutional investors have recently made changes to their positions in the stock. UBS Oconnor LLC purchased a new position in shares of Auris Medical Holding AG during the first quarter valued at approximately $909,000. Perceptive Advisors LLC bought a new position in Auris Medical Holding AG during the first quarter valued at about $368,000. Sabby Management LLC bought a new position in Auris Medical Holding AG during the first quarter valued at about $133,000. Finally, Virtu KCG Holdings LLC bought a new position in Auris Medical Holding AG during the second quarter valued at about $101,000. 28.41% of the stock is owned by institutional investors and hedge funds.

About Auris Medical Holding AG

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Get a free copy of the Zacks research report on Auris Medical Holding AG (EARS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Auris Medical Holding AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical Holding AG and related companies with Analyst Ratings Network's FREE daily email newsletter.